Chugai Pharmaceutical (OTCMKTS:CHGCY) Releases Quarterly Earnings Results

Chugai Pharmaceutical (OTCMKTS:CHGCY) issued its earnings results on Thursday. The company reported $0.25 earnings per share (EPS) for the quarter, Zacks reports. Chugai Pharmaceutical had a net margin of 32.74% and a return on equity of 20.63%.

Chugai Pharmaceutical Trading Up 2.8%

OTCMKTS CHGCY traded up $0.76 during trading hours on Thursday, reaching $28.28. The company’s stock had a trading volume of 18,874 shares, compared to its average volume of 117,130. The stock has a market cap of $93.07 billion, a PE ratio of 35.35 and a beta of 0.63. The business has a 50-day simple moving average of $26.72 and a 200 day simple moving average of $24.39. Chugai Pharmaceutical has a 52 week low of $19.50 and a 52 week high of $31.26.

Wall Street Analyst Weigh In

Separately, UBS Group upgraded Chugai Pharmaceutical to a “strong-buy” rating in a research note on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, According to MarketBeat, Chugai Pharmaceutical currently has a consensus rating of “Strong Buy”.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd. is a Japan-based biopharmaceutical company headquartered in Tokyo that focuses on the discovery, development, manufacture and marketing of prescription medicines. The company develops both biologics and small-molecule therapies, with particular emphasis on oncology and immunology as well as treatments for bone and metabolic disorders. Chugai’s activities span the full drug lifecycle from early research and clinical development through regulatory approval, manufacturing and post-marketing support.

Chugai is known for its research-driven approach and its work on monoclonal antibodies and other biologic therapeutics.